The IVIS® SpectrumBL is an advanced high-throughput 2D and 3D optical imaging system designed to improve quantitative outcomes of bioluminescent, chemiluminescent and Cerenkov in vivo imaging.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
For research use only. Not for use in diagnostic procedures.
The SpectrumBL supports 10 mice simultaneous imaging for true high throughput imaging for longitudinal studies to support large cohorts of mice. It uses a patented optical imaging technology to facilitate non-invasive longitudinal monitoring of disease progression, cell trafficking and gene expression patterns in living animals.
Features & Benefits:
|21 CFR Part 11 Compatible||No|
|Imaging Modality||Optical Imaging|
|Product Brand Name||IVIS|
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.
Influenza is a highly infectious airborne disease with an important societal burden. Annual epidemics have occurred throughout history causing tens of millions of deaths. Even a run-of-the-mill influenza infection can be debilitating to otherwise healthy people, and lethal to those who are elderly or frail, so vaccinations are important. Because of seasonal antigenic drift and antiviral resistance of the virus there is a critical need for the development of new and novel vaccines and antiviral drugs. In vivo optical imaging has emerged as a powerful, non-invasive tool to track viral load and therapeutic efficacy of vaccines and immunotherapies in small animal models.
Read how researchers at the NIH, NIAID, Emory University, and University of Wisconsin used the IVIS® optical imaging platform to successfully quantify and track viral load in mice and demonstrated that vaccine of human mAb administration has a protective or therapeutic effect in mice challenged with the influenza virus.
Auto-exposure technical note for IVIS pre-clinical imaging systems
Subtracting Background ROI from a Sequence
DLIT setup and acquisition IVIS pre-clinical imaging systems. Bioluminescence Tomography or Diffuse Light Imaging Tomography (DLIT) utilizes the data obtained from a filtered 2D bioluminescent sequence in combination with a surface topography to represent the bioluminescent source in a 3D space. Utilizing DLIT, you can determine the depth of sources in your animal and calculate the absolute intensity of that source.
DLIT 2 Topography technical note for IVIS Spectrum imaging system. The IVIS Spectrum has a laser galvanometer that we routinely use to project the FOV onto the surface of the instrument. It produces the green outline you see on the stage when the door is opened. We utilize this laser to project a series of parallel lines across your subject. We acquire a photographic image (the Structured Light Image) when the lines are projected across the animal and from that image we can calculate the height at points on the back of your subject based on the curvature of these laser lines as they cross over the subject. This height map allows us to reconstruct a shell or isosurface of your animal. This shell is referred to as the Surface Topography and is used in calculating bioluminescent signal depth and intensity during the DLIT 3D source reconstruction.
DLIT 3 Reconstruction technical note for IVIS Spectrum imaging systems
Determine Saturation for IVIS imaging systems - technical note
Technical notes for Drawing ROIs for IVIS in vivo imaging systems. The circle, square, free draw, or grid (for well plates) can be used to draw your ROIs. ROI selections,are user-specific and are dependent on the model being analyzed. It is irrelevant which shape that is used for a particular ROI.
Acquisition of High Resolution Images. This quick reference guide is for those researchers who wish to perform analysis that requires high resolution including in vitro studies when one may want to discern aspects about cell layers, ex vivo tissue imaging, or imaging of tissue slices. You will not need this resolution in most in vivo studies.
Acquiring the most accurate quantitation of your bioluminescent sources requires a close understanding of the underlying kinetics involved in producing and capturing the detected light. After injection, the substrate for your bioluminescent probe will di
Subject ROI using IVIS imaging systems
Viral diseases have emerged and re-emerged throughout history, and as the human population continues to increase globally, so will the frequency of viral pandemics. Not only have Ebola and COVID-19 demonstrated most recently mankind’s vulnerability to contagious diseases, but also the challenges we are faced with from a therapeutic standpoint.Read how non-invasive optical imaging enables the most intricate host-pathogen interactions to be visualized and monitored in disease models that mimic what is seen in humans. Not only does optical imaging play an important role in better understanding the complex mechanisms of viral biology, it plays a vital role in the discovery and development of new drug and vaccine candidates.
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.